Market Place
Sourcing Support
Spinogenix Appoints Steve Young to Board of Directors
25 Nov 2024 //
GLOBENEWSWIRE
Spinogenix Launches Glaucoma Program With Dr. Robert Weinreb
16 Oct 2024 //
GLOBENEWSWIRE
Spinogenix Launches Phase 2 Trial For SPG302 In Schizophrenia
25 Sep 2024 //
GLOBENEWSWIRE
Spinogenix Opens Enrollment For Alzheimer`s SPG302 Phase 2 Study
01 Aug 2024 //
GLOBENEWSWIRE
Spinogenix Opens Enrollment For Phase 2 Trial Of SPG601 In Fragile X
23 Jul 2024 //
GLOBENEWSWIRE
Spinogenix Receives Approval To Start Phase 2 Trial Of SPG302 For Alzheimer’s
20 Jun 2024 //
GLOBENEWSWIRE
Spinogenix Gets FDA IND Clearance For ALS Therapy SPG302
29 May 2024 //
GLOBENEWSWIRE
Spinogenix`s SPG601 Granted FDA Orphan Drug For Fragile X
20 May 2024 //
GLOBENEWSWIRE
US FDA clears Spinogenix’s IND application for SPG601 to treat FraX Syndrome
17 Apr 2024 //
PHARMABIZ
Spinogenix Gets IND For Fragile X SPG601 Phase 2a
15 Apr 2024 //
GLOBENEWSWIRE
Spinogenix Announces Second Grant Award from U.S. DoD to Further Advance SPG302
26 Sep 2023 //
GLOBENEWSWIRE
Spinogenix Receives Approval to Initiate Phase 1 Human Clinical Trial of SPG302
10 Jul 2023 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.